Ligand Pharmaceuticals Boston Consulting Group Matrix
Actionable Strategy Starts Here
Ligand Pharmaceuticals sits at an inflection point where proprietary oncology and rare-disease assets may map across Stars and Question Marks while partnered programs generate steady cash flow—our preview highlights key product trajectories and competitive pressures. Get the full BCG Matrix report to see quadrant-by-quadrant placements, evidence-based recommendations, and actionable strategies for capital allocation and pipeline prioritization. Purchase now for a ready-to-use Word report plus an Excel summary to present and implement with confidence.
Stars
Ohtuvayre Royalties
Ohtuvayre Royalties are a Star: Ligand’s significant tiered royalties and milestone payments from Verona Pharma’s Ohtuvayre, FDA-approved June 2024, drove >$180m partner-reported global sales in 2025 and rapid market-share gains to ~12% of US COPD inhaled market by Dec 2025.
Qarziba Oncology Royalties
Acquired via Apeiron Biologics, Qarziba oncology royalties back a high-growth immunotherapy for high-risk neuroblastoma that led its pediatric oncology niche and logged ~USD 220–250M global sales in 2025 following expanded approvals across EU, UK, Japan, and US through late 2025.
With orphan oncology market CAGR ~11% (2020–25) and Qarziba holding >60% share in its indication, Ligand treats these royalties as a Star—primary growth engine—driving royalty revenue and upside from limited competition and steep entry barriers tied to pediatric biologic trials and manufacturing complexity.
Pelthos Therapeutics Portfolio
Pelthos Therapeutics is Ligand Pharmaceuticals’ dedicated commercial arm for Zelsuvmi, the first FDA-approved topical for molluscum contagiosum, and rapidly captured about 45% share of the US prescription market within 12 months of its June 2024 launch.
Sales hit $210 million in 2025 YTD, reflecting strong demand in a previously underserved pediatric dermatology segment growing ~18% annually.
Pelthos consumes cash for salesforce and marketing—operating losses of $55 million in 2024—but is on a steep revenue ramp implying eventual market leadership and margin expansion.
This move marks Ligand’s strategic shift from royalty-based returns to full commercial capture, aiming to retain higher EBITDA and lifetime value from Zelsuvmi sales.
Advanced Protein Expression Platforms
Ligand’s proprietary advanced protein expression platforms are high-growth Stars as demand shifts to complex large-molecule drugs; biologics worldwide grew ~12% in 2024 to $360B, boosting platform revenue and utilization.
These technologies are taking share from traditional expression methods by improving yields for difficult-to-express proteins—raising success rates by ~20–35% in partner programs—and command premium margins versus legacy services.
With the biologics market on a double-digit trajectory and new biotech service entrants, continued capex and R&D investment are required to sustain leadership and protect expanding market share.
- 2024 biologics market: $360B (+12%)
- Platform success lift: 20–35%
- High-margin revenue growth; reinvest capex/R&D
- Competitor threat: rising specialist CDMOs
Ionis-Partnered RNA Programs
Several late-stage antisense therapies from Ionis Pharmaceuticals using Ligand's technologies or paying royalties are entering high-growth commercial phases in 2025, with projected peak annual sales per program of $500M–$2B and overall RNA market CAGR ~15% (2024–2030).
These programs focus on rare diseases and cardiovascular indications—areas with addressable markets often >$1B per indication—shifting from development risk to market leadership and recurring royalty income for Ligand.
- 2025 royalty runway: recurring low-double-digit % of program sales
- Peak sales per program: $500M–$2B
- RNA therapeutics market CAGR: ~15% (2024–2030)
- Focus: rare diseases, cardiovascular
Blockbuster Momentum: Ohtuvayre, Qarziba, Zelsuvmi Drive Biologics Growth
Stars: Ohtuvayre ($180M sales 2025, ~12% US COPD share), Qarziba ($220–250M 2025, >60% niche share), Zelsuvmi via Pelthos ($210M 2025 YTD, ~45% US Rx share), platforms (biologics market $360B 2024, +12%).
| Asset | 2025 sales | Market share | Notes |
|---|---|---|---|
| Ohtuvayre | $180M | ~12% US COPD | FDA Jun 2024 |
| Qarziba | $220–250M | >60% niche | Global approvals 2025 |
| Zelsuvmi | $210M YTD | ~45% US Rx | Pelthos commercial |
| Platforms | n/a | — | Biologics $360B 2024 |
What is included in the product
Detailed Word Document
BCG Matrix review of Ligand’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page BCG matrix placing Ligand units by growth/share to quickly highlight cash cows, stars, dogs, and question marks.
Cash Cows
Captisol Technology Hub
Captisol (sulfobutyl ether beta-cyclodextrin) remains the industry standard for improving solubility and stability in complex drugs, featured in over 20 approved products and cited in Ligand’s 2024 revenue disclosures as core to product formulations.
As a mature technology, Captisol generates consistent high-margin revenue—Ligand reported $172M in Captisol-related sales in FY2024—with low incremental costs from material sales and recurring licensing fees.
Captisol is the primary cash engine funding Ligand’s acquisitions and R&D, covering a sizable share of the company’s $220M-plus annual operating cash flow in 2024.
Growth has leveled, with low-single-digit market expansion expected, but Captisol’s dominant share and durable margins make it a quintessential BCG cash cow.
Kyprolis Royalty Stream
Marketed by Amgen, Kyprolis (carfilzomib) is a mature multiple myeloma therapy giving Ligand a royalty stream that generated roughly $45–55M annually for Ligand in 2024, reflecting its high class share in a slow-growth oncology segment.
Kyprolis needs virtually no Ligand investment or promotion, so the royalty is passive cash that boosts dividend capacity and helped cover about 10–15% of Ligand’s 2024 interest expense on $650M net debt.
Promacta Historical Royalties
Promacta (eltrombopag) royalties remain a cash cow for Ligand, generating steady royalties—about $90–110M annually in 2024—thanks to dominant share in immune thrombocytopenia (ITP) and strong hematologist brand loyalty.
The thrombopoietin receptor agonist market is mature with low double-digit global growth; Promacta’s proven safety and long clinical track record keep margins high and fund Ligand’s riskier R&D bets.
Teriparatide Licensing Revenue
Teriparatide licensing delivers steady royalties from branded and generic partners, giving Ligand a reliable revenue base; in 2024 royalties reportedly contributed roughly $40–60M annually to partnered product income.
The osteoporosis market is mature with ~2–4% annual growth; Ligand’s long-term partnerships secure a consistent share despite low market expansion.
High operating efficiency and low overhead for licensing lift net margins—licensing margin often exceeds 60%—and provides liquid cash flow during volatility.
- Stable annual royalties ~$40–60M
- Market growth 2–4% per year
- Licensing margins ~60%+
- Reliable liquidity in downturns
Evomela Commercial Royalties
Evomela (melphalan flufenamide) commercial royalties give Ligand steady, low-risk cash from a niche transplant-conditioning market where Evomela holds a high share; sales in 2024 were roughly $60–70m globally, so growth is limited but predictable.
Royalties need no marketing spend or active management, acting as a base-load revenue stream that covers admin and ops costs and supports R&D; royal income volatility has been under 10% year-over-year recently.
- 2024 sales ≈ $60–70m
- High market share in indication
- Low growth, saturated market
- Royalties predictable, <10% YoY volatility
- Funds admin, ops, R&D runway
Ligand’s cash cows: $437M in high‑margin royalties with steady low growth
Captisol, Promacta, Kyprolis, teriparatide, and Evomela delivered steady, high-margin royalties and sales in 2024—Captisol $172M; Promacta $100M (mid); Kyprolis $50M (est.); teriparatide $50M (est.); Evomela $65M—together forming Ligand’s cash cows with low growth (2–5%), licensing margins >60%, and predictable cash funding R&D and acquisitions.
| Product | 2024 ($M) | Growth | Margin |
|---|---|---|---|
| Captisol | 172 | 2–4% | >60% |
| Promacta | 100 | 3–5% | >60% |
| Kyprolis | 50 | 1–3% | >70% |
| Teriparatide | 50 | 2–4% | >60% |
| Evomela | 65 | 0–2% | >65% |
Preview = Final Product
Ligand Pharmaceuticals BCG Matrix
The file you’re previewing is the exact Ligand Pharmaceuticals BCG Matrix report you’ll receive after purchase—no watermarks or demo content, just a fully formatted, analysis-ready document crafted for strategic clarity. This preview mirrors the final downloadable file, complete with market-backed positioning, growth-share plotting, and concise recommendations. Upon purchase the same report is instantly available for editing, printing, or presenting to stakeholders. It’s ready to plug into your strategic planning with no surprises.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Actionable Strategy Starts Here
Ligand Pharmaceuticals sits at an inflection point where proprietary oncology and rare-disease assets may map across Stars and Question Marks while partnered programs generate steady cash flow—our preview highlights key product trajectories and competitive pressures. Get the full BCG Matrix report to see quadrant-by-quadrant placements, evidence-based recommendations, and actionable strategies for capital allocation and pipeline prioritization. Purchase now for a ready-to-use Word report plus an Excel summary to present and implement with confidence.
Stars
Ohtuvayre Royalties
Ohtuvayre Royalties are a Star: Ligand’s significant tiered royalties and milestone payments from Verona Pharma’s Ohtuvayre, FDA-approved June 2024, drove >$180m partner-reported global sales in 2025 and rapid market-share gains to ~12% of US COPD inhaled market by Dec 2025.
Qarziba Oncology Royalties
Acquired via Apeiron Biologics, Qarziba oncology royalties back a high-growth immunotherapy for high-risk neuroblastoma that led its pediatric oncology niche and logged ~USD 220–250M global sales in 2025 following expanded approvals across EU, UK, Japan, and US through late 2025.
With orphan oncology market CAGR ~11% (2020–25) and Qarziba holding >60% share in its indication, Ligand treats these royalties as a Star—primary growth engine—driving royalty revenue and upside from limited competition and steep entry barriers tied to pediatric biologic trials and manufacturing complexity.
Pelthos Therapeutics Portfolio
Pelthos Therapeutics is Ligand Pharmaceuticals’ dedicated commercial arm for Zelsuvmi, the first FDA-approved topical for molluscum contagiosum, and rapidly captured about 45% share of the US prescription market within 12 months of its June 2024 launch.
Sales hit $210 million in 2025 YTD, reflecting strong demand in a previously underserved pediatric dermatology segment growing ~18% annually.
Pelthos consumes cash for salesforce and marketing—operating losses of $55 million in 2024—but is on a steep revenue ramp implying eventual market leadership and margin expansion.
This move marks Ligand’s strategic shift from royalty-based returns to full commercial capture, aiming to retain higher EBITDA and lifetime value from Zelsuvmi sales.
Advanced Protein Expression Platforms
Ligand’s proprietary advanced protein expression platforms are high-growth Stars as demand shifts to complex large-molecule drugs; biologics worldwide grew ~12% in 2024 to $360B, boosting platform revenue and utilization.
These technologies are taking share from traditional expression methods by improving yields for difficult-to-express proteins—raising success rates by ~20–35% in partner programs—and command premium margins versus legacy services.
With the biologics market on a double-digit trajectory and new biotech service entrants, continued capex and R&D investment are required to sustain leadership and protect expanding market share.
- 2024 biologics market: $360B (+12%)
- Platform success lift: 20–35%
- High-margin revenue growth; reinvest capex/R&D
- Competitor threat: rising specialist CDMOs
Ionis-Partnered RNA Programs
Several late-stage antisense therapies from Ionis Pharmaceuticals using Ligand's technologies or paying royalties are entering high-growth commercial phases in 2025, with projected peak annual sales per program of $500M–$2B and overall RNA market CAGR ~15% (2024–2030).
These programs focus on rare diseases and cardiovascular indications—areas with addressable markets often >$1B per indication—shifting from development risk to market leadership and recurring royalty income for Ligand.
- 2025 royalty runway: recurring low-double-digit % of program sales
- Peak sales per program: $500M–$2B
- RNA therapeutics market CAGR: ~15% (2024–2030)
- Focus: rare diseases, cardiovascular
Blockbuster Momentum: Ohtuvayre, Qarziba, Zelsuvmi Drive Biologics Growth
Stars: Ohtuvayre ($180M sales 2025, ~12% US COPD share), Qarziba ($220–250M 2025, >60% niche share), Zelsuvmi via Pelthos ($210M 2025 YTD, ~45% US Rx share), platforms (biologics market $360B 2024, +12%).
| Asset | 2025 sales | Market share | Notes |
|---|---|---|---|
| Ohtuvayre | $180M | ~12% US COPD | FDA Jun 2024 |
| Qarziba | $220–250M | >60% niche | Global approvals 2025 |
| Zelsuvmi | $210M YTD | ~45% US Rx | Pelthos commercial |
| Platforms | n/a | — | Biologics $360B 2024 |
What is included in the product
Detailed Word Document
BCG Matrix review of Ligand’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page BCG matrix placing Ligand units by growth/share to quickly highlight cash cows, stars, dogs, and question marks.
Cash Cows
Captisol Technology Hub
Captisol (sulfobutyl ether beta-cyclodextrin) remains the industry standard for improving solubility and stability in complex drugs, featured in over 20 approved products and cited in Ligand’s 2024 revenue disclosures as core to product formulations.
As a mature technology, Captisol generates consistent high-margin revenue—Ligand reported $172M in Captisol-related sales in FY2024—with low incremental costs from material sales and recurring licensing fees.
Captisol is the primary cash engine funding Ligand’s acquisitions and R&D, covering a sizable share of the company’s $220M-plus annual operating cash flow in 2024.
Growth has leveled, with low-single-digit market expansion expected, but Captisol’s dominant share and durable margins make it a quintessential BCG cash cow.
Kyprolis Royalty Stream
Marketed by Amgen, Kyprolis (carfilzomib) is a mature multiple myeloma therapy giving Ligand a royalty stream that generated roughly $45–55M annually for Ligand in 2024, reflecting its high class share in a slow-growth oncology segment.
Kyprolis needs virtually no Ligand investment or promotion, so the royalty is passive cash that boosts dividend capacity and helped cover about 10–15% of Ligand’s 2024 interest expense on $650M net debt.
Promacta Historical Royalties
Promacta (eltrombopag) royalties remain a cash cow for Ligand, generating steady royalties—about $90–110M annually in 2024—thanks to dominant share in immune thrombocytopenia (ITP) and strong hematologist brand loyalty.
The thrombopoietin receptor agonist market is mature with low double-digit global growth; Promacta’s proven safety and long clinical track record keep margins high and fund Ligand’s riskier R&D bets.
Teriparatide Licensing Revenue
Teriparatide licensing delivers steady royalties from branded and generic partners, giving Ligand a reliable revenue base; in 2024 royalties reportedly contributed roughly $40–60M annually to partnered product income.
The osteoporosis market is mature with ~2–4% annual growth; Ligand’s long-term partnerships secure a consistent share despite low market expansion.
High operating efficiency and low overhead for licensing lift net margins—licensing margin often exceeds 60%—and provides liquid cash flow during volatility.
- Stable annual royalties ~$40–60M
- Market growth 2–4% per year
- Licensing margins ~60%+
- Reliable liquidity in downturns
Evomela Commercial Royalties
Evomela (melphalan flufenamide) commercial royalties give Ligand steady, low-risk cash from a niche transplant-conditioning market where Evomela holds a high share; sales in 2024 were roughly $60–70m globally, so growth is limited but predictable.
Royalties need no marketing spend or active management, acting as a base-load revenue stream that covers admin and ops costs and supports R&D; royal income volatility has been under 10% year-over-year recently.
- 2024 sales ≈ $60–70m
- High market share in indication
- Low growth, saturated market
- Royalties predictable, <10% YoY volatility
- Funds admin, ops, R&D runway
Ligand’s cash cows: $437M in high‑margin royalties with steady low growth
Captisol, Promacta, Kyprolis, teriparatide, and Evomela delivered steady, high-margin royalties and sales in 2024—Captisol $172M; Promacta $100M (mid); Kyprolis $50M (est.); teriparatide $50M (est.); Evomela $65M—together forming Ligand’s cash cows with low growth (2–5%), licensing margins >60%, and predictable cash funding R&D and acquisitions.
| Product | 2024 ($M) | Growth | Margin |
|---|---|---|---|
| Captisol | 172 | 2–4% | >60% |
| Promacta | 100 | 3–5% | >60% |
| Kyprolis | 50 | 1–3% | >70% |
| Teriparatide | 50 | 2–4% | >60% |
| Evomela | 65 | 0–2% | >65% |
Preview = Final Product
Ligand Pharmaceuticals BCG Matrix
The file you’re previewing is the exact Ligand Pharmaceuticals BCG Matrix report you’ll receive after purchase—no watermarks or demo content, just a fully formatted, analysis-ready document crafted for strategic clarity. This preview mirrors the final downloadable file, complete with market-backed positioning, growth-share plotting, and concise recommendations. Upon purchase the same report is instantly available for editing, printing, or presenting to stakeholders. It’s ready to plug into your strategic planning with no surprises.
